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Abstract
Background: Glomerular damage in IgA nephropathy (IgAN) is mediated by complement activation via the
alternative and lectin pathways. Therefore, we focused on molecules stabilizing and regulating the alternative
pathway C3 convertase in urine which might be associated with IgAN pathogenesis.
Methods: Membrane attack complex (MAC), properdin (P), factor H (fH) and Complement receptor type 1 (CR1)
were quantified in urine samples from 71 patients with IgAN and 72 healthy controls. Glomerular deposition of C5,
fH and P was assessed using an immunofluorescence technique and correlated with histological severity of IgAN
and clinical parameters. Fibrotic changes and glomerular sclerosis were evaluated in renal biopsy specimens.
Results: Immunofluorescence studies revealed glomerular depositions of C5, fH and P in patients with IgAN.
Urinary MAC, fH and P levels in IgAN patients were significantly higher than those in healthy controls (p < 0.001),
but CR1 was significantly lower than that in healthy controls (p < 0.001). Urinary MAC and fH levels were positively
correlated with serum creatinine (sCr), urinary N-acetyl-b-D-glucosaminidase (u-NAG), urinary b2 microglobulin
(u-Bm), urinary protein (p < 0.001), interstitial fibrosis (MAC: p < 0.01, fH: p < 0.05) and the percentage of global
glomerular sclerosis (p < 0.01). Urinary P was positively correlated with u-NAG, u-Bm, and urinary protein (p < 0.01).
Conclusions: Complement activation occurs in the urinary space in IgAN and the measurement of levels of MAC
and fH in the urine could be a useful indicator of renal injury in patients with IgAN.
Background
IgA nephropathy (IgAN) is the most common form of
glomerular disease worldwide. Predominant deposition of
IgA1 and C3 in mesangial areas is accepted as a hallmark
diagnostic feature of IgAN. Immunohistological findings
on complement components showed deposits of C3 and
properdin (P) in the glomerular mesangial areas and the
absence of C1q in patients with IgAN [1-3]. Thus, it has
been thought that the activation of the alternative path-
way plays a crucial role in the pathogenesis of IgAN.
However, recent studies revealed that 25% of patients
with IgAN had mesangial deposits of mannose-binding
lectin (MBL), L-ficolin, MBL-associated serine protease
and C4, suggesting that the lectin pathway activation may
also be important in some IgAN patients [4-7]. In any
event, activation of C3 and C3 convertase production are
the key causes of histological damage induced following
membrane attack complex (MAC; C5b-9) formation.
MAC is produced via the activated common terminal
pathway of all three complement pathways.
There are several proteins which stabilize or regulate C3
convertase activation via the alternative or lectin pathways.
C 3 b B bi sa nu n s t a b l ef o r mo fC 3c o n v e r t a s ew i t hah a l f -
life of 90 seconds. C3bBb associates with and is stabilized
by P, to form the C3bBbP, with a half-life extended 5-10-
fold [8]. Factor H (fH) plays a crucial role in inhibition of
the alternative pathway by the following mechanism: 1) fH
is a cofactor for factor I (fI) in cleaving C3b to inactivate
C3bi [9,10] and 2) fH accelerates the decay of C3b, Bb,
and C3bBbP [11]. Complement receptor type 1 (CR1;
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specificity for C3b and C4b with the ability to displace the
catalytic subunits from C3 or C5 convertase and to func-
tion as a co-factor for the degradation of C3b and C4b
mediated by factor I [12,13].
Because our previous work established that the serum
levels of B, P, fH and fI in patients with IgAN were signifi-
cantly higher than those in healthy controls [14], we
hypothesized that targeting the alternative pathway C3
convertase activation could be therapeutically beneficial in
IgAN. In other types of glomerular disease, such as mem-
branous nephropathy and lupus nephritis, patients’ urine
contains complement regulatory proteins and MAC,
amounts of which fluctuate with disease activity [15-17].
Here, we investigated these issues using urine samples
from patients with IgA nephropathy, which, unlike serum,
can be obtained noninvasively.
Methods
Patients and controls
Seventy-one patients with IgAN (38 males and 33
females), who had been referred to Juntendo University
Hospital between March 2003 and May 2005, were
enrolled. Age of these patients at the time of urine collec-
tion ranged from 16 to 67 years old (37.8 ± 12.8, mean ±
SD). Normal controls were 72 healthy volunteers (58
males and 14 females). This study was approved by the
institutional human study Ethics Committee and informed
consent was obtained before participation. Histological
diagnosis was classified by standard examination of renal
biopsy specimens by light microscopic findings with the
results of immunoglobulin and complement deposition by
immunofluorescence technique. According to the Japanese
Clinical Guidelines for Patients with IgAN [18], patients
were divided into four groups as follows: good prognosis,
relatively good prognosis, relatively poor prognosis and
poor prognosis (Table 1).
Laboratory data
Serum total protein (TP), urinary protein (urinary pro-
tein (mg/dl)/urinary creatinine (mg/dl)), urinary
N-acetyl-b-D-glucosaminidase (u-NAG), urinary b2-
microglobulin (u-Bm) and serum levels of urea nitrogen
(SUN), and creatinine (s-Cr) were measured as part of
the routine clinical analyses at the time of urine collec-
tion. Laboratory data were undertaken at the central
laboratory in the Juntendo University Hospital.
Glomerular deposition of Immunoglobulins, C1q, C3, C5,
fH and P
Renal biopsy specimens wer ef r o z e na n de x a m i n e db y
direct immunofluorescence staining, performed using
fluorescein-5-isothiocyanate-labeled rabbit anti-human
IgG, IgA, IgM, C1q and C3 antisera (Dako, Denmark),
goat anti-human C5 and P antisera (Nordic Immunologi-
cal Laboratories, Tilburg, Netherlands), and rabbit anti-
human fH antiserum labeled by Linkit™ Fluoro-Link (ISL,
Paignton, UK). IgG, IgA, IgM, C1q and C3 were diluted to
1:50 in 0.01 mol/l PBS, ph7.4, and C5, fH and P were
diluted to 1:10 in the same buffer.
Measurement of complement regulatory proteins and
MAC in urine
Urine samples were obtained and stored at -80°C until use.
Rabbit antisera to human fH, P, CR1, and purified P were
kindly provided by Professor Teizo Fujita (Department of
Biochemistry, Fukushima Medical University, Japan). Bio-
tinylated anti-human properdin antibody was purchased
from AntibodyShop (Gentofte, Denmark).
Urinary concentrations of fH and MAC were measured
by commercially available sandwich enzyme-linked immu-
nosorbent assay (ELISA) kits (BTA TRAK Kit, Alidex,
Inc., Redmond, WA, USA, and SC5b-9 EIA, Quidel, San
Diego, CA, USA). ELISA for P and CR1 were developed in
our institute. Urinary P was quantified as described in our
Table 1 Histological severity of IgAN (Japanese Clinical Guidelines )
Mesangial
cell
proliferation
and
increased
matrix
Glomerulosclerosis,
crescent formation
or adhesion to
Bowman’s capsule
Interstitium,
renal tubuli
or blood vessels
Good
prognosis
Slight Absent Prominent changes are not seen
Relatively good
prognosis
Slight < 10% of all
biopsied glomeruli
Prominent changes are not seen
Relatively
poor prognosis
Moderate,
diffuse
10-30% of all
biopsied glomeruli
Cellular infiltration is slight in the interstitium except around some sclerosed glomeruli.
Tubular atrophy is slight, and mild vascular sclerosis.
Poor
prognosis
Severe,
diffuse
> 30% of all
biopsied glomeruli
Interstitial cellular infiltration and tubular atrophy, as well as fibrosis are seen. Hyperplasia
or degeneration may be seen in some intrarenal arteriolar walls.
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μg/ml rabbit anti-human CR1 antibody and 0.1 μg/ml bio-
tinylated mouse anti-human CR1 antibody (Ancell Cor-
poration, Bayport, MN, USA) [19].
Western blot analysis for urinary fH
To obtain a detectable amoun to fu r i n a r yf H ,t h eu r i n e
samples were concentrated fourfold by Ultrafree-MC
Centrifugal Filter Units (Millipore, Bedford, MA, USA).
Urine samples were electrophoresed on 5% SDS-PAGE
gradient gels under non-reducing conditions and the
resultant bands were transferred to Immobilon™ (Milli-
p o r e ,B e d f o r d ,M A ,U S A ) .T h ei m m u n o b l o t sw e r ei n c u -
bated with biotinylated mouse anti-human fH antibody
(AntibodyShop, Gentofte, Denmark), and incubated with
streptavidin-peroxidase (Streptavidin-HRP, Southern Bio-
technology Associates, Inc. Birmingham, AL, USA), and
then developed using the ECL-plus system (Amersham
Biosciences, Little Chalfont, UK).
Evaluation of fibrotic changes and glomerular sclerosis
Fibrotic changes were evaluated on Azan and Masson-
Trichrome-stained slides from 60 cases. Interstitial fibro-
sis was assessed by measuring the percentage of fibrotic
(collagen-positive) area against whole area of specimen,
using the KS400 Carl Zeiss image analysis system
(KS400, Carl Zeiss Imaging Solutions GmbH, Hallberg-
moos, Germany).
The percentage of global glomerular sclerosis as a
fraction of all glomeruli was determined in 39 renal
biopsy specimens by light microscopy.
Statistical analysis
Data are shown as mean ± SD. Comparisons among the
groups were performed by the Mann-Whitney U test, and
comparisons of the four classifications were performed by
the Bonferroni’s Multiple Comparison test. Correlations
among the groups were evaluated by linear regression.
P values < 0.05 were considered significant in all analyses.
Results
Patients’ background
All patients with IgAN were classified according to the
Japanese Clinical Guidelines [18] and their clinical char-
acteristics are shown in Table 2. U-NAG levels in the
poor prognosis group were significantly higher than
those in the other groups (p < 0.05). Significant differ-
ences in levels of TP, s-Cr and urinary protein were
observed among the four groups. Regarding differences
associated with disease severity, levels of urinary MAC
were increased; especially in the poor prognosis group it
was tending significantly higher than in the good prog-
nosis group.
Glomerular deposition of complement components and
regulatory proteins
Immunofluorescence technique revealed deposits of C3,
C5, fH and P in glomeruli of IgAN patients (Figure 1).
The coarse granular deposits of all these factors
appeared to have a similar mesangial distribution pat-
tern. From these results, we inferred that the alternative
pathway C3 convertase was activated and regulated in
the IgAN glomeruli.
Urinary MAC and complement regulatory proteins
Urinary complement components in IgAN patients and
healthy controls are shown in Figure 2. In IgAN patients,
urinary MAC, fH, and P levels were significantly higher
than those in healthy controls (Figure 2A, B, C), whereas
urinary CR1 was significantly lower (Figure 2D). Figure 3
shows the relationship between urinary MAC, fH, P, CR1
and disease severity. In particular, levels of urinary MAC
Table 2 Clinical characteristics of the patients
Classification
(The number of biopsies and range of glomeruli)
TP
(g/dl)
s-Cr
(mg/dl)
u-Protein
(g/g￿Cr)
u-NAG
(10
-3U/mg￿Cr)
u-Bm
(ng/mg￿Cr)
u-MAC
(ng/mg￿Cr)
Good prognosis
(n = 6, 7.5 ± 4.5)
7.3 ± 0.6 0.64 ± 0.18 0.41 ± 0.19 3.6 ± 2.3* 57.7 ± 17.3 0.3 ± 0.8
Relatively good prognosis
(n = 17, 15.3 ± 9.6)
7.4 ± 0.3** 0.80 ± 0.19 0.39 ± 0.36* 3.6 ± 2.0* 110.2 ± 113.1 6.5 ± 11.0
Relatively poor prognosis
(n = 30, 13.0 ± 6.9)
7.0 ± 0.5 0.72 ± 0.23* 0.75 ± 0.67 4.5 ± 2.2* 222.9 ± 570.5 12.1 ± 24.9
Poor prognosis
(n = 18, 14.9 ± 9.6)
6.8 ± 0.4 0.98 ± 0.48 1.10 ± 0.92 9.3 ± 6.7 254.4 ± 528.3 25.4 ± 42.7
Total
(n = 71)
7.1 ± 0.5 0.80 ± 0.32 0.72 ± 0.70 5.4 ± 4.4 189.9 ± 458.4 14.0 ± 28.4
(mean ± SD)
*: p < 0.05 vs. poor prognosis,
**:p < 0.05 vs. relatively poor prognosis and poor prognosis
Abbreviations: TP, total protein; s-Cr, serum creatinine; u-Protein, urinary protein; u-NAG, urinary N-acetyl-b-D-glucosaminidase; u-Bm, u-b2 microglobulin; u-MAC,
urinary membrane attack complex
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severity (p < 0.001).
Correlations between urinary complement and clinical
markers for renal disease were sought (Table 3). Urinary
MAC was significantly correlated with s-Cr (p < 0.01),
u-NAG (p < 0.001), u-Bm (p < 0.001) and urinary protein
(p < 0.001). There was also a significant correlation
between fH and all parameters (p < 0.001). Levels of urin-
ary MAC and fH dovetail with clinical disease activity.
Levels of urinary CR1 were significantly correlated with
u-Bm (p < 0.01), but there was no significant correlation
between CR1 and any other parameters.
Molecular weight of urinary fH
The molecular weight of urinary fH was evaluated by Wes-
tern blotting in 7 patients with levels >50 U/mg·Cr (Figure
4). Serum fH had an estimated molecular weight of 150
kDa in all patients, as well as in the healthy controls. There
was no fH in the urine of healthy controls. Urinary fH in
IgAN patients was also 150 kDa, except for one patient
whose urine had the highest level of fH and contained a 42
kDa protein (factor H like protein 1: FHL-1).
Urinary complement and histological changes
Correlations between urinary complement levels and
interstitial fibrosis, and between urinary complement
levels and percentage of global glomerular sclerosis,
were evaluated in IgAN patients (Table 4). Urinary
MAC was significantly correlated with interstitial fibro-
sis (p < 0.01) and the percentage of global glomerular
sclerosis as a fraction of all glomeruli (p < 0.01). Urinary
fH levels were significantly correlated with interstitial
fibrosis (p < 0.05) and the percentage of global glomeru-
lar sclerosis (p < 0.01).
Significant correlations were also found between inter-
stitial fibrosis and urinary protein (r = 0.421, p < 0.01),
and between percentage of global glomerular sclerosis
and urinary protein (r = 0.339, p < 0.01).
Figure 1 Glomerular deposition of C3, C5, fH and P were assessed by immunofluorescence technique. Glomerular deposition of C3, C5,
fH and P shows the same mesangial pattern.
Onda et al. BMC Nephrology 2011, 12:64
http://www.biomedcentral.com/1471-2369/12/64
Page 4 of 8Discussion
IgAN is the most common chronic glomerulonephritis
with one third of patients developing progressive end-stage
renal failure [20,21]. Although complement activation leads
to tissue damage in IgAN, the role of complement
regulatory proteins in the pathogenesis of IgAN has not
been clearly defined. Our previous report and others docu-
mented increased serum levels of fH and P in IgAN
patients and that serum levels of complement regulatory
proteins reflected IgAN disease activity [14,22]. Based on
Figure 2 Urinary MAC and complement regulatory protein levels differ between patients with IgA nephropathy and healthy controls.
Levels of urinary MAC, fH, and P are significantly higher in IgAN patients than those in healthy controls, but CR1 is significantly lower.
Figure 3 Levels of urinary MAC and complement regulatory proteins in IgA nephropathy patients grouped according to disease
severity. Urinary MAC, fH and P tends to increase with worsening of prognosis, in particular, MAC and fH significantly fluctuate with disease
prognosis (p < 0.001).
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urinary complement components in the pathogenesis of
IgAN.
In other renal diseases, strong associations of urinary fH
and MAC levels with disease progression have been
demonstrated (15-17). Recently, Zang et al. proposed that
urinary fH in patients with IgAN may be a useful biomar-
ker to evaluate kidney injury [23]. In that report, the analy-
sis was limited to urinary fH. Here, we extend our
evaluation to other proteins, namely, P, CR1 and MAC.
We found that levels of urinary MAC, fH and P in patients
with IgAN were significantly higher than those in healthy
controls. Furthermore, urinary MAC and fH levels were
significantly increased with increasing disease severity.
Urinary MAC levels reflected disease state in patients with
IgAN, as is the case in other nephropathies [24]. Urinary
fH and P, which are involved in the regulation and stabili-
zation of the alternative pathway C3 convertase, might
also be associated with renal damage. Although only 4
patients had taken steroids when they were collected the
urine samples, results of complement components pre-
sented not particular tendency.
In renal disease, renal function is closely related to
tubulo-interstitial injury, part of which is due to MAC for-
mation on tubular epithelial cells [25]. Indeed, urinary fH
and P levels were strongly correlated with u-NAG and
might reflect the occurrence of intra-tubular activation of
C3. In additional work, we did find significant correlations
between urinary fH and P (p < 0.001), fH and MAC (p <
0.001), and P and MAC (p < 0.001) (data not shown).
The human fH family consists of seven multi-domain
and multifunctional serum proteins, including fH itself
(MW 150 kDa), factor H-like protein 1 (FHL-1) (MW 42
kDa) and five factor H-related proteins (FHR-1, -2, -3, -4
and -5) [26]. This study demonstrated that fH, a 150 kDa
protein, was detected in patients’ urine samples, but lower
MW members of this family were not detected in IgAN,
with the exception of one patient with FHL-1. Because
human mesangial cells and proximal tubular epithelial
cells are capable of producing fH [27,28], urinary fH might
be derived from glomeruli and/or tubules, not from the
blood.
Previous studies showed that synthesis of membrane-
bound CR1 on the podocytes is reduced in patients with
advanced glomerular disease [29,30]. Urinary CR1 was
released from podocytes, and did not originate from ery-
throcyte CR1 and soluble CR1 [31]. Likewise, as estab-
lished here, urinary CR1 in patients with IgAN was
significantly lower than in healthy controls.
There was a significant correlation between interstitial
fibrosis and the percentage of global glomerular sclerosis
as a fraction of all glomruli (p < 0.01). Thus, tubulointer-
stitial damage may be affected by glomerular injury. There
were significant correlations between interstitial fibrosis
and urinary protein, and between the percentage of global
glomerular sclerosis and urinary protein. It was previously
Table 3 Correlations between levels of urinary MAC and complement regulatory proteins in IgAN patients
MAC fH P CR1
rprprprp
s-Cr 0.297 p < 0.01 0.531 p < 0.001 0.192 p = 0.102 -0.174 p = 0.137
u-NAG 0.589 p < 0.001 0.633 p < 0.001 0.419 p < 0.001 0.491 p = 0.481
u-Bm 0.414 p < 0.001 0.384 p < 0.001 0.367 p < 0.01 0.323 p < 0.01
u-Protein 0.458 p < 0.001 0.645 p < 0.001 0.502 p < 0.001 -0.181 p = 0.122
Abbreviations: MAC, membrane attack complex; fH, factor H; P, properdin; CR1, complement receptor 1; s-Cr, serum creatinine; u-NAG, urinary N-acetyl-b-D-
glucosaminidase; u-Bm, u-b2 microglobulin; u-Protein, urinary protein
Figure 4 Detection of fH in urine and serum samples by Western blotting. Representative results show molecular weight assessments for
fH. Lane 1: purified fH, lane 2: urine a from patient, 3: serum from the same patient, 4: urine from a healthy control, 5: serum from a healthy
control, 6: urine from the patient with the highest level of urinary fH.
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glomerular damage and interstitial fibrosis. Therefore,
interstitial fibrosis and the percentage of global glomerular
sclerosis might be a marker of renal damage. Urinary fH
and MAC were significantly correlated with interstitial
fibrosis and the percentage of global glomerular sclerosis.
Moreover, MAC showed a better correlation with intersti-
tial fibrosis than did urinary protein, and fH correlated
better with global sclerosis than urinary protein in patients
with IgAN. Urinary fH showed a better correlation with
serum creatinine, urinary NAG, urinary protein and global
sclerosis than urinary MAC in patients with IgAN. It is
proposed that in fact, fH might not regulate complement
activation and subsequent formation of MAC. Therefore,
MAC formation and renal damage might occur in IgAN.
Further research is needed to clarify whether the relation-
ships between urinary fH and complement activation
might recapitulate in other types of glomerulonephritis.
Conclusions
Complement activation occurs in the urinary space in
IgAN and the measurement of levels of MAC and fH in
the urine could be a useful indicator of renal injury in
patients with IgAN.
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